EW Taylor1

Ethan Will Taylor, Ph.D.

Senior Research Professor, Nanoscience

Phone: 336.285.2873

Fax: 336.500.0115

Email: ewtaylor@uncg.edu

Research Website


Research Interests

Interests and research activities of the Taylor lab encompass areas ranging from structural bioinformatics, molecular modeling and drug design, to applied molecular biotechnology, nanotechnology and virology.

Molecular modeling, bioinformatics, gene discovery and identification: Our research often begins with theoretical genomic analysis, using various bioinformatics tools, to develop hypotheses about biological structure and mechanisms, which are then validated in the “wet lab” by molecular biological methods. This approach is applied to various problems of biomedical interest. A key accomplishment is our demonstration that the genomic complexity of some viruses is greater than previously thought. In the case of HIV-1 we have demonstrated the existence of several novel viral proteins encoded in “hidden” genes, and shown that they function as previously predicted by theory. These findings have implications for the role of dietary antioxidants, and the trace mineral selenium in particular, in modulating viral pathogenesis.

HIV pathogenesis and therapeutics development: Research is being conducted into novel mechanistic approaches for treating HIV and other viral infections, including approaches that try to block or reverse the detrimental effects of HIV in the body rather than targeting the virus itself (e.g., based upon metabolic and nutritional factors), and approaches based on the elimination of HIV-infected cells. Such approaches also have a greatly reduced potential for the emergence of drug resistance, compared to current anti-HIV drugs.

Other research projects: In collaboration with other labs, we have ongoing projects ranging from nanomedicine and biomedical diagnostic device development to angiogenesis inhibition in ocular diseases. The latter involves the study of both vascular endothelial growth factor (VEGF) and Toll-like receptor 3 (TLR3) as targets for the development of angiogenesis inhibitors, based on molecular modeling of the protein-protein and protein-RNA interactions involved.

Selected Publications

Office Hours

By Appointment

Education

NIH Postdoc, Medicinal Chemistry

University of Arizona, 1986-1987

Ph.D. Pharmacology and Toxicology

University of Arizona, 1985

B.Sc. Organic Chemistry and Biochemistry

University of Winnipeg , 1981